Business Update France: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Business Update France.

Press releases published on June 23, 2026

Jun. 23, 2026

BitSpider Returns to Profitability Following Coinstone's Increased Stake; to Apply for MiCA Authorisation by 30 June

Indeterminate EIN Presswire

Jun. 23, 2026

DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index

Indeterminate GlobeNewswire

Jun. 23, 2026

DBV Technologies intégrera l’Indice Euronext Tech Leaders

Indeterminate GlobeNewswire

Jun. 23, 2026

Top Retail Media Thought Leaders Have 'Conversation at Cannes' Webinar to Address Promising Tactic’s Most Vexing Issues

Indeterminate EIN Presswire

Jun. 23, 2026

Apptunix Launches Mobile App Development Services in Germany

Indeterminate EIN Presswire

Jun. 23, 2026

GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma

Indeterminate GlobeNewswire

Jun. 23, 2026

GENFIT : Données positives de Phase 1b obtenues avec GNS561 en combinaison, dans une population de patients atteints de cholangiocarcinome lourdement prétraités

Indeterminate GlobeNewswire

Jun. 23, 2026

ReVIBES Project 1re étape, COBRA&Kosuke Kawamura adjugé, montrant le potentiel entre œuvres cultes et pop art

Indeterminate EIN Presswire

Jun. 23, 2026

Comfort Keepers Adopts HomeSight to Deliver the Next Generation of Connected Home Care

Indeterminate GlobeNewswire

Jun. 23, 2026

Nokia advances autonomous networks portfolio with upgraded agentic AI capabilities #DTW26

Indeterminate GlobeNewswire

Jun. 23, 2026

Press Release: Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia

Indeterminate GlobeNewswire

Jun. 23, 2026

Communiqué de presse : Wayrilz de Sanofi a été approuvé au Japon pour traiter la thrombocytopénie immunitaire

Indeterminate GlobeNewswire

Jun. 23, 2026

Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses

Indeterminate GlobeNewswire

Jun. 23, 2026

Communiqué de presse : Cenrifki (tolebrutinib) de Sanofi approuvé dans l’UE comme premier médicament ciblant la progression du handicap dans la sclérose en plaques secondairement progressive sans rechutes

Indeterminate GlobeNewswire